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Background: In the past few years, an increasing number of studies have reported the potential use of
microRNAs (miRNA) as circulating biomarkers for diagnosis or prognosis of a wide variety of diseases.
There is, however, a lack of reproducibility between studies. Due to the high miRNA content in platelets
this may partly be explained by residual platelets in the plasma samples used. When collecting fresh
plasma samples, it is possible to produce cell-free/platelet-poor plasma by centrifugation. In this study,
we systematically investigated whether biobanked EDTA plasma samples could be processed to be
suitable for miRNA analysis.
Materials and methods: Blood samples were collected from ten healthy volunteers and centrifuged to
produce platelet-poor-plasma (PPP) and standard biobank plasma. After one week at 80 °C the bio-
banked EDTA plasma was re-centrifuged by different steps to remove residual platelets. Using RT-qPCR
the levels of 14 miRNAs in the different plasma preparations were compared to that of PPP.
Results: We were able to remove residual platelets from biobanked EDTA plasma by re-centrifugation of
the thawed samples. Nevertheless, for most of the investigated miRNAs, the miRNA level was sig-
niﬁcantly higher in the re-centrifuged biobanked plasma compared to PPP, even when the platelet count
was reduced to 0–1109/L.
Conclusion: We found, that pre-storage centrifugation conditions have a signiﬁcant impact on the
measured EDTA plasma level of miRNAs known to be present in platelets. Even for the miRNAs found to
be less effected, we showed that a 1.5–3 fold change in plasma levels may possible be caused by or easily
overseen due to sample preparation and/or storage.
& 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
MicroRNAs (miRNAs) are short, single-stranded non-coding
RNAs acting as posttranscriptional regulators of gene expression
[1]. In the circulation cell-free miRNAs are protected against de-
gradation as they are included in microvesicles or exosomes or
they are bound to high-density lipoproteins or to the argonaute
2 protein complex [2]. MiRNAs were ﬁrst identiﬁed in Cae-
norhabditis elegans in 1993 [3], but it took almost a decade before
they were discovered in mammals [4,5], and the ﬁrst reports of
circulating miRNAs came in 2008 [6,7]. In the past few years, an
increasing number of studies have reported the potential use of
miRNAs as circulating biomarkers for diagnosis or prognosis of a
wide variety of diseases such as cancers [8,9], cardiovascularB.V. This is an open access article u
, reverse transcription poly-
. Binderup).diseases [10], diabetes [11] and mental illness [12]. However, in
only a minority of studies where miRNAs were reported to be
differently expressed in healthy and diseased individuals, the re-
sults have been conﬁrmed by others [13]. Pre-analytical conditions
are a major source of variation in and between miRNA studies,
and have been addressed by several studies in the past few years
[2,14–19]. An important factor to consider is cellular remnants in
the samples, for example in hemolysis where disruption of ery-
throcytes causes a signiﬁcant increase in the plasma/serum levels
of many miRNAs [15]. Furthermore, due to residual platelets, the
levels of some miRNAs are higher in routine plasma samples
compared to routine serum samples [14], and certain other miR-
NAs are found in higher levels in serum compared to plasma,
probably due to their release from leucocytes and/or platelets
during the coagulation process [20]. When collecting fresh sam-
ples, it is possible by additional centrifugation steps to produce
cell-free/platelet-poor plasma, but many studies are performed
using biobanked routine plasma samples with variable number of
residual platelets. In this study we will systematically investigatender the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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suitable for miRNA analysis, when investigating the plasma levels
of miRNAs known to be present in platelets.2. Materials and methods
From each of 10 healthy volunteers 310 mL of K2-EDTA an-
ticoagulated venous blood were collected using a 21 gauge needle
after a minimum of venous stasis, and discard of the ﬁrst 5 mL of
blood drawn (tubes and needles were obtained from Becton-
Dickinson, Franklin Lakes, NJ, USA).
A schematic overview of the sample preparation can be seen in
Fig. 1. All the centrifugation steps were carried out at 20 °C.
In order to obtain platelet-poor-plasma (PPP) 10 mL of EDTA
anticoagulated whole blood was centrifuged at 3000 g for 15 min.
After centrifugation the plasma phase was carefully transferred to
another tube, leaving approximately one mL of plasma on top of
the buffy coat. The centrifugation step was repeated on the re-
maining plasma, and again approximately one mL was left in the
bottom of the tube when the platelet-poor-plasma was transferred
into cryo-tubes (labeled PPP) for storage at 80 °C.
Ten mL of EDTA anticoagulated whole blood was centrifuged at
2000 g for 10 min, which is standard procedure in our laboratory
when collecting plasma for biobanking. After centrifugation the
total amount of plasma from the 10 mL collection tube was
transferred to another tube (labeled biobank), and stored at
80 °C. After one week the biobank-plasma was thawed and
gently mixed. A volume of 1.5 mL was transferred to a cryotube
(labeled biobank A). The remaining material was centrifuged at
3000 g for 15 min, and the plasma was transferred to a cryotube
(labeled biobank B) leaving approximately one mL in the bottom of
the centrifuge tube.
From each of the two plasmas (biobank A/B) 300 μL of plasma
was collected for miRNA-isolation, before the remaining plasma
was further centrifuged. Biobank A samples were centrifuged at
3000 g for 30 min and biobank B samples at 3000 g for 15 min.
The prolonged centrifugation of the biobank A samples wasFig. 1. Schematic overview over the different plasma preparations. A total of 10 mL of w
10 mL whole blood were handled according to our laboratory protocol for preparation of
further processed to eliminate platelet contamination (biobank A, A2, B and B2). As illu
Plasma from the other tube was pipetted from the top of the tube mL by mL to investiperformed, to investigate whether a longer one-step centrifuga-
tion could eliminate platelet contamination as efﬁcient as a
shorter two-step centrifugation. After centrifugation the plasma
was transferred to new tubes (labeled biobank A2 and B2, re-
spectively), leaving approximately 200 μL in the bottom of the
centrifuged tubes. From each of the two plasmas (biobank A2/B2)
300 μL of plasma was collected for miRNA-isolation. MiRNA was
isolated, as described below, immediately following the plasma
preparation procedure without any further freezing/thawing of the
samples.
In order to investigate the distribution of platelets in the
plasma phase 10 mL of EDTA anticoagulated whole blood was
centrifuged at 2000 g for 10 min. After centrifugation the plasma
was transferred to new tubes one mL at a time from the top of the
collection tubes. In total, 4 mL of plasma (labeled gradient A to D)
was collected from each 10 mL whole blood.
After each centrifugation step and from each gradient-sample
200 μL of plasma was collected for platelet count analysis which
was performed using the fully automated Sysmex XE 5000 ana-
lyzer (Sysmex, Kobe, Japan).
2.1. MiRNA analysis
MiRNA was isolated from 300 μL of each of the plasma pre-
parations PPP, Biobank A, Biobank B, Biobank A2 (only the six
samples with a platelet count of 0–1109/L) and Biobank B2 using
NucleospinsmiRNA Plasma (Macherey-nagel, Germany) and ac-
cording to protocol supplied by the manufacturer. As a mean of
normalization all samples were spiked with 5 μL Cel-miR-39
(2.751012 M) (RiboTask, Odense, Denmark). The spike was
added after removal of the plasma proteins in the same step as
isopropanol. MiRNA was eluted using 30 μL of RNAse free water,
and the samples were frozen at 20 °C. MiRNA-analysis was
performed within one month from the time of miRNA-isolation.
cDNA synthesis was performed using TaqMansMicroRNA Re-
verse Transcription Kit and Custom TaqMan MIR RT Pool (both
from Applied Biosystems, Life Sciences). The RT-primer pool,
which was designed for a previous study of platelet derivedhole blood was used for the preparation of platelet poor plasma (PPP). Two tubes of
biobank plasma. Plasma from one of the tubes was frozen for one week, thawed and
strated, after freezing and thawing of the biobank plasma we denote it biobank A.
gate the distribution of platelets in the plasma phase (gradient A–D).
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primers for 14 miRNAs known to be present in platelets and cel-
miR-39. The reaction was performed using 3 μL of RNA-sample in
a total volume of 10 μL.
As the miRNA level in plasma is relatively low, a pre-
ampliﬁcation step was performed using 5 μL of the RT-product in a
total reaction volume of 25 μL containing TaqMansPreAmp Mas-
ter Mix and Custom TaqMan MIR PreAmp Pool (Applied
Biosystems).
The ﬁnal quantiﬁcation was performed using Custom Taq-
MansArray MicroRNA Cards (TLDA) from Applied Biosystems. A
total of 1.2 μL of the preampliﬁcation products were diluted with
TaqMansUniversal Master Mix II, no UNG and loaded onto the
array. The miRNAs were analyzed in triplets using the ABI Prism
7900HT, and single outliers were removed before calculating the
mean Ct-values for each miRNA.
MiRNA levels were normalized using either the exogenous cel-
miR-39 or the endogenous miR-16, and calculated as 2ΔCt (ΔCt¼
Cttarget miRNACtcel-miR-39 or ΔCt¼Cttarget miRNACtmiR-16).
The measured miRNA levels in the different plasma prepara-
tions were evaluated using PPP as reference, and fold changes
were calculated as 2ΔΔCt.
2.2. Statistical analysis
All statistical calculations were carried out using R version
3.2.3. [21]. As data were not normally distributed we used the
Wilcoxon signed rank test for comparison of the miRNA levels in
the different plasma preparations and the levels in PPP. P-values
r0.05 were considered signiﬁcant.3. Results
3.1. Residual platelet count
Platelet count was found to be low in all PPP (0–1109/L) but
to vary signiﬁcantly in the 13000 (range 9–49109/L), biobank
(range 53–195109/L) and biobank B (range 2–16109/L)Fig. 2. Residual platelet count in the different plasma preparations. Platelet count in the d
count is relatively high and vary signiﬁcantly in the biobank (equals biobank A, but h
preparations still contain some platelets. After further processing of the samples the p
samples.preparations (Fig. 2). After an additional centrifugation of the
biobank A/B samples the platelet count was 0–1109/L in all
biobank B2 and in six of the biobank A2 samples. The remaining
four biobank A2 samples still contained a small number of plate-
lets (range 2–4109/L).
3.2. Platelet distribution in the plasma phase
To evaluate a potential platelet gradient through the plasma
phase, we investigated the distribution of platelets in the plasma
of a 10 mL collection tube after a 10 min centrifugation at 2000 g.
We found platelets to be equally distributed in the plasma phase of
samples from the 10 volunteers (Fig. 3) except for the last gradient
plasma (gradient D) in two samples which contained a higher
number of platelets.
3.3. MiRNA levels
To evaluate the effect on miRNA levels of different residual
platelet count in biobanked plasma samples, we compared the
miRNA levels in the different plasma preparations with the levels
in PPP (Table 1 and Supplementary Figs. 1 and 2). When preparing
the biobank A2/B2 samples, an additional centrifugation step was
used as an effort to eliminate any remaining platelets from the
biobank A/B samples. Despite this additional centrifugation step,
four biobank A2 samples still contained a small amount of plate-
lets, and to ensure a sample population with minimal platelet
contamination, we chose not to use these four samples for miRNA-
analysis. Therefore, miRNA-analysis was performed on PPP, bio-
bank A, biobank B and biobank B2 samples from ten volunteers,
and on the six biobank A2 samples with a platelet count of
0–1109/L.
MiRNA levels were normalized using either the exogenous cel-
miR-39 or the endogenous miR-16 as reference gene. When nor-
malized to cel-miR-39, levels of miR-16 were found to be sig-
niﬁcantly (po0.05) higher in biobank A, A2 and B samples com-
pared to PPP samples (1.6–2.6 fold in average). Therefore, the fold
changes in miRNA levels between the different plasma prepara-
tions and PPP found for the other investigated miRNAs were lowerifferent plasma preparations from the 10 volunteers. It can be seen that the platelet
as not been frozen) and 3000 g for 15 min preparations, and that the biobank B
latelet count was 0–1109/L in all PPP, all biobank B2 and six of the biobank A2
Fig. 3. Platelet count in the four gradient samples from each of ten volunteers. For
each of the ten volunteers are plotted the median platelet count of the four gra-
dient samples A–D, and the lines illustrates the minimum and maximum value. The
highest platelet count in samples from volunteer 3 and 7 were seen in gradient D,
which is the plasma phase just above the buffy coat.
Table 1
MiRNA levels in the different plasma preparations relative to PPP.
MicroRNA Plasma type Normalized to cel-mir-
39
Normalized to miR-16
Average fold
change from
PPP
P-value Average fold
change from
PPP
P-value
miR-142–3p Biobank A 37.3 o0.01 11.0 o0.01
BiobankA2 5.2 o0.05 2.8 o0.05
Biobank B 4.7 o0.01 5.8 o0.01
BiobankB2 4.1 o0.01 2.4 o0.01
miR-145 Biobank A 68.4 o0.01 22.5 o0.01
BiobankA2 4.9 o0.05 2.3 o0.05
Biobank B 6.6 o0.01 6.2 o0.01
BiobankB2 3.0 o0.01 1.8 o0.01
miR-16 Biobank A 2.6 o0.01
BiobankA2 1.9 o0.05
Biobank B 1.2 0.43
BiobankB2 1.6 o0.01
miR-26a Biobank A 92.3 o0.01 24.1 o0.01
BiobankA2 2.4 o0.05 0.9 0.35
Biobank B 9.2 o0.01 7.2 o0.01
BiobankB2 1.4 0.56 0.7 o0.05
miR-28 Biobank A 102.5 o0.01 34.2 o0.01
BiobankA2 13.2 o0.05 6.8 o0.05
Biobank B 9.3 o0.01 7.9 o0.01
BiobankB2 6.3 o0.01 3.0 o0.01
miR-301 Biobank A 84.0 o0.01 24.4 o0.01
BiobankA2 14.2 o0.05 6.2 o0.05
Biobank B 11.8 o0.01 8.4 o0.01
BiobankB2 13.0 o0.01 5.9 o0.01
miR-30a-5p Biobank A 9.8 o0.01 4.7 o0.01
BiobankA2 3.7 o0.05 2.2 0.17
Biobank B 2.5 o0.05 2.8 o0.01
BiobankB2 2.4 o0.01 1.7 o0.01
miR-30d Biobank A 14.9 o0.01 5.7 o0.01
BiobankA2 2.8 o0.05 1.4 0.25
Biobank B 3.8 o0.01 4.0 o0.01
BiobankB2 2.4 o0.01 1.4 o0.01
miR-328 Biobank A 94.1 o0.01 30.7 o0.01
BiobankA2 368 o0.05 233 o0.05
Biobank B 23.0 o0.01 16.9 o0.01
BiobankB2 97.4 o0.01 53.6 o0.01
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normalization using cel-miR-39 (Table 1). Still, regardless of the
choice of normalization, we found signiﬁcantly higher levels of all
the investigated miRNAs in biobank A/B samples compared to PPP
samples (po0.05), which was expected as these plasmas had
high/medium residual platelets content.
Furthermore, when using cel-miR-39 for normalization we
found signiﬁcantly higher levels (Po0.05) of all investigated
miRNAs in the six biobank A2 samples (1.9–368 fold on average)
and of all investigated miRNAs except miR-26a in the biobank B2
samples (1.6–97.4 fold on average) as compared to PPP samples.
Alongside that, miRNA levels normalized to miR-16 were found to
be signiﬁcantly higher (po0.05) for 10 of the investigated miRNAs
in biobank A2 samples (2.3–233 fold on average) and for all of
the investigated miRNAs except miR-26a in biobank B2 samples
(1.4–53.6 fold on average). The level of miR-30a-5p and miR-30d
were found to be higher (1.4–2.2 fold on average), but not sig-
niﬁcantly different between biobank A2 and PPP samples
(p40.05). Levels of miR-26a were found to be slightly lower in
biobank A2/B2-samples compared to PPP, and in A2 samples the
difference was not signiﬁcant.miR-331 Biobank A 63.5 o0.01 20.9 o0.01
BiobankA2 113.1 o0.05 48.9 o0.05
Biobank B 8.4 o0.01 6.6 o0.01
BiobankB2 55.8 o0.01 31.3 o0.01
miR-335 Biobank A 95.1 o0.01 28.4 o0.01
BiobankA2 26.9 o0.05 11.4 o0.05
Biobank B 17.1 o0.01 14.4 o0.01
BiobankB2 19.1 o0.01 9.3 o0.01
miR-340 Biobank A 53.7 o0.01 18.4 o0.01
BiobankA2 8.3 o0.05 4.1 o0.05
Biobank B 11.4 o0.01 10.5 o0.01
BiobankB2 5.2 o0.01 3.8 o0.01
miR-92a Biobank A 8.4 o0.01 2.7 o0.01
BiobankA2 13.8 o0.05 6.5 o0.05
Biobank B 2.5 o0.05 2.1 o0.01
BiobankB2 8.6 o0.01 3.9 o0.01
miR-93 Biobank A 13.1 o0.01 4.3 o0.01
BiobankA2 4.9 o0.05 2.6 o0.05
Biobank B 3.5 o0.01 2.8 o0.01
BiobankB2 3.8 o0.01 1.9 o0.01
Average fold change in miRNA level relative to PPP are given for biobank A, A2, B
and B2 samples. MiRNA levels are normalized to cel-miR-39 and miR-16, respec-
tively. Biobank A preparations represent the standard biobank plasma (centrifuged
at 2000 g for 10 min) after one freezing/thawing cycle. P-values were calculated
using the Wilcoxon signed rank test, and were considered signiﬁcant if o0.05.4. Discussion
Circulating miRNA may have great potential as biomarkers for
many diseases, and many studies have addressed associations
between disease status and miRNA levels in biobanked plasma or
serum samples [22–24]. As platelets contain large amounts of
miRNA [25], residual platelets may contribute signiﬁcantly to the
miRNA levels in plasma, and therefore platelets should be re-
moved prior to miRNA analysis. During freezing and/or thawing of
the plasma, miRNAs may be released from residual platelets and
contribute to the miRNA levels even despite of an additional
centrifugation step after thawing of the plasma. To evaluate bio-
banked plasma as a suitable material for miRNA-analysis, or
whether it can be transformed into such, we performed a range of
centrifugation steps on biobanked plasma samples, after which we
analyzed the plasma preparations for their residual platelet con-
tents as well as miRNA levels.
When using our standard procedure for biobanking (cen-
trifugation of whole blood for 10 min at 2000 g) plasma contained
a relatively high number of platelets (Fig. 2). A further cen-
trifugation of the biobanked plasma for 15 min at 3000 g reduced,
but did not fully eliminate residual platelets, whereas a two-step
centrifugation at these conditions or a 30 min centrifugation at
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platelet content (0–1109/L). A total of four samples still con-
tained a small number of platelets after the 30 min centrifugation,
probably due to disturbance of the pellet when plasma was
transferred.
In order to evaluate whether these centrifugation steps could
also eliminate contamination with miRNAs derived from residual
platelets during sample storage, we used RT-qPCR analysis to
compare the level of 14 selected miRNAs in the different plasma
preparations to that of PPP. We found the level of most in-
vestigated miRNAs to be signiﬁcantly higher in all plasma pre-
parations compared to PPP (Table 1 and Supplementary Figs. 1 and
2), except for miR-26a levels in biobank B2 samples (with either
normalization strategy) and the levels of miR-26, miR-30a-5p and
miR-30d in the biobank A2 samples (when normalized to miR-16).
For miR-328, miR-331 and to a minor extent miR-92a the level was
signiﬁcantly higher in the biobank A2/B2 samples compared to the
biobank A/B samples, though the biobank A2/B2 samples have
very low platelet content. The plasma level of miR-328 is very low,
and analytical limitations could explain our ﬁndings for this
miRNA, but this is not the case for miR-331 or miR-92a. Zheng et.
al. also found a few miRNAs that were present in plasma after high
speed centrifugation, but not detectable in plasma centrifuged at
only 820 g [16]. A possible explanation for these ﬁndings could be
the content of different miRNAs in microvesicles of different sizes,
but further studies are needed to ascertain the reason and im-
portance of this difference between miRNAs.
Cheng et.al. reported that an additional centrifugation step
after thawing of biobanked samples could minimize the sig-
niﬁcance of the plasma preparation prior to freezing [17]. They
found that centrifugation of thawed plasma samples at 1940 g for
10 min reduced the average platelet count from 80109/L to
10109/L and the plasma level of a number of miRNAs by several
fold, as example miR-142–3p was reduced by 5 fold, miR-16 by
1.8 fold and miR-92a by 2.0 fold. These results are a little lower,
but comparable with our ﬁndings when comparing biobank A and
biobank B samples, normalizing miRNA levels to cel-miR-39 and
taking into account the differences in centrifugation time and
speed (our centrifugation was 3000 g for 15 min). In the study by
Cheng et.al. the investigators did not include samples from which
all platelets was removed prior to freezing, and our present study
illustrates that even when residual platelets are almost completely
removed after thawing of biobanked samples, they still contain a
signiﬁcantly higher level of platelet derived miRNA compared to
PPP. As an example, when using cel-miR-39 for normalization we
found the plasma level of miR-142-3p to be 5.2 fold higher in the
biobank A2 samples and 4.1 fold higher in the biobank B2 samples
compared to PPP. Using miR-16 for normalization the fold changes
were 2.8 and 2.4, respectively. In recent publications miR-142–3p
has been reported to be signiﬁcantly up- or down- regulated in
different diseases/conditions, in some studies by 1.5–3 fold [26–31]
and in other studies by 4.8–19 fold [32–34]. Our results indicate
that a 1.5–3 fold change in plasma levels of this miRNA may pos-
sibly be caused by or could easily be overseen due to differences in
sample preparation and/or storage. We found miR-26a to be only
slightly affected by sample preparation prior to freezing, never-
theless, the observed differences between the biobank A2/B2
samples and PPP of up to 2.4 fold, still reaches the level of changes
in miRNA levels reported by a handful of recent studies [35–39].
We did not examine the impact of the platelet count before cen-
trifugation, but since the platelet count ranges across approxi-
mately 3-fold in healthy patients and up to 100-fold in diseased
patients, preanalytical conditions might be of even greater im-
portance and different sample preparation may be needed in case
of very high platelet count.
When preparing PPP we ﬁrst centrifuged the whole bloodsamples, and then performed a re-centrifugation of the plasma,
both centrifugations at 3000 g for 15 min. A study by Chandler
found that a two-step centrifugation of platelet-rich plasma at
1500 g for 20 min removed 99% of the platelets, but also 58–93% of
platelet-derived microparticles [40]. Therefore, as miRNA released
from activated cells are often included in microparticles [41,42], an
effort to eliminate platelet contamination, may affect the mea-
sured level of many circulating miRNAs due to a reduction in the
number of microparticles. This dilemma illustrates the need of a
standardized protocol for sample preparation, in order to compare
results obtained in different laboratories.
Since a routine centrifugation at 2000 g does not eliminate all
platelets from the plasma, a platelet gradient may exist that could
inﬂuence measured miRNA levels. To evaluate this, we in-
vestigated the platelet distribution in the plasma phase of 10 mL
blood collection tubes from 10 volunteers. We found the platelets
to be equally distributed throughout the plasma phase in most
tubes, only the plasma closest to the buffy coat (gradient D) from
two volunteers contained a higher number of platelets. When
collecting 4 mL of plasma from 10 mL of whole blood, the volume
of plasma left on the buffy coat vary depending on the hematocrit,
and the higher platelet count observed in the two gradient D
plasmas may possible be due to a higher hematocrit in these vo-
lunteers. Our results indicate that it is not important from which
plasma phase the samples for miRNA analysis origin, but care
should be taken to avoid the buffy coat.
The present study has some limitations, including the relatively
small sample size, the fact that we did not investigate other ma-
trices than EDTA plasma and that we did not include miRNAs not
present in platelets.
In conclusion, our results show that the pre-storage cen-
trifugation conditions have a signiﬁcant impact on the measured
EDTA plasma level of miRNAs known to be present in platelets.
Even for the miRNAs found to be less effected, we found that a 1.5–
3 fold change in plasma levels may possible be caused by or easily
overseen due to sample preparation and/or storage. Thus, in order
to compare miRNA levels of plasma samples within or between
studies, it is essential to use standardized sampling and processing
protocols and to report these in details in future publications.Funding
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